Car­dio event forces FDA to halt a Penn PhII study for mul­ti­ple myelo­ma

Just a few months af­ter be­gin­ning a Phase II clin­i­cal tri­al of a new mul­ti­ple myelo­ma drug, in­ves­ti­ga­tors at the Uni­ver­si­ty of Penn­syl­va­nia have been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.